17 MoUs for Academia –Industry Linkages signed between NIPERs and Pharma Industry
17 MoUs for Academia –Industry Linkages signed
between NIPERs and Pharma Industry; Pharma initiative to build Innovation
Ecosystem in India
One of the critical factors in building innovation
ecosystem and for Drug Discovery is Academia-Industry linkage. Department of
Pharmaceuticals for the last one year has actively engaged both the NIPERs and
the Pharma Industry to build partnership in areas of education, research and
development. The result is that 7 National Institutes for Pharmaceutical
Education and Research (NIPERs) have undertaken Academia-Industry linkage with
17 Pharma Industries of Private and Public sector. These 7 NIPERs exchanged MOUs
with Industry heads in the presence of H.E.President of India Pranab Mukherjee
on 4th November 2015 as a part of Visitors conference being
held now 4-6th November 2015. During the event, a total
of 45 MOUs were exchanged between Central Institutions viz., IITs, NIPERs,
IISERs,IIITs, IISc-B, NIFT, NITs, RGIPT, RGNIYD& SPAs. Of the 45, 17 are
under Pharmaceuticals sector. Thus the initiative of Department of
Pharmaceuticals stands out.
India enjoys
global leadership in Pharmaceutical sector in Generic medicines. Department of
Pharmaceuticals celebrates the achievements of both Public and Private Pharma
Industry for their contribution in India’s self-reliance on medicines. Globally
India ranks 3rd largest in volume and 10th in
value. Every third tablet consumed globally is made in India. Exports are
being made to more than 200 Countries with a major share in regulated markets.
Much of the credit goes to policy initiative in terms of Patent Act, 1970 which
allowed process patents, enabling in transforming India from medicine importing
country to exporting country and Private and Public skill and entrepreneurship
of Pharma Industry.
Pharma sector is a knowledge intensive science and
technology based industry. Indian domestic pharma market is around Rs.1.00 lakh
crores and its analysis suggests that patent medicines constitute less than 1%
share illustrating poor accessibility/ availability of latest innovative
medicines in the face of growing non-communicable diseases like cancer because
of affordability. This issue reiterates the urgency for India to have paradigm
shift in its strategy to expand its leadership in Drug Discovery and Innovation
after post-WTO, TRIPS regime.India’s leadership in Drugs Discovery will not
only make medicines affordable and will surely pave a way for India becoming a
prosperous nation addressing the poverty as well. High risk and High investment
are the hallmarks of drugs discovery.
High quality manpower is one of the critical
requirements for its success. It is under these circumstances that the
Government of India has set up NIPERs for nurture and produce high quality
manpower for making India a global leader in Drugs Discovery. NIPERs are
Institutions of National importance set up under NIPER Act, 1998 on the lines
of IITs. Presently there are 7 NIPERs functional at Mohali, Ahmedabad,
Guwahati, Hajipur, Hyderabad, Kolkata and Raebareli. One more NIPER at Madurai
is in process of setting up. During 2015-16 2 new NIPERs were announced for
Chattisgarh, Maharashtra and Rajasthan state.
Further in India, the research and development in
Pharmaceuticals sector is spread across a number of Ministries and Departments
viz., Department of Bio-Technology, Dept.of Science and Technology, Department
Scientific and Industrial Research, Health Systems Research (ICMR) and
Dept.of Pharmaceuticals. It is under these circumstances that the Department of
Pharmaceuticals is drawing up a common road map for Drug Discovery through
convergence and synergy involving all stakeholders.
Department of Pharmaceuticals has identified that
Academia-Industry linkage as a basic requirement for translating research into
development (commercialization) and Innovation; and also to fix accountability
among the Educational Institutions. The initiative will be a historic
event in the annals of Department of Pharmaceuticals in its endeavour of making
India a global leader in Drugs Discovery.
MoU details are provided below:
NIPER
|
PRIVATE
PHARMA INDUSTRY
|
SUBJECT OF THE MoU
|
Hyderabad
|
1. Dr.
Reddy’s Labs
|
Exchange of scientific personnel for Education &
Training; Research collaboration; Finishing school and Dr. Reddy’s Chair
|
|
Exchange of scientific personnel for Education and
Training and research collaboration
|
|
|
3. NATCO
|
Exchange of scientific personnel for Education and
Training and research collaboration
|
Ahmedabad
|
4. Cadila
Pharmaceuticals
|
Exchange of scientific personnel for Education and
Training and Research collaboration
|
|
5. Cadila
Healthcare (Zyudus)
|
Exchange of scientific personnel for Education and
Training and Research collaboration
|
|
6. Sahjanand
Technologies
|
Curriculum Development, Education and Industry project
work to students
|
|
7. Johnson
& Johnson
|
Curriculum Development, Education and Industry project
work to students
|
Mohali
|
8. Sun Pharma
|
Formulation Development
|
|
9. Wockahardt
|
Research and development in anti-inflammatory and life-style
disease segments
|
|
10. Panacea
Biotech
|
Collaborative Research in the areas of Metabolic
Disorders, CNS disorders, Oncology and Infectious diseases
|
|
11. Medley
Pharmaceuticals Ltd.
|
Formulation development in the area of Hematinics, Anti
ulcerants, anti-bacterials, pain management, gynaecology and cardiovascular
|
With Central Public Sector
Enterprises
NIPER
|
CPSE
|
SUBJECT OF THE MOU
|
Mohali
|
12. Rajasthan
Drugs and Pharmaceuticals Ltd.
|
Formulation Development and Training
|
Ahmedabad
|
13. Hindustan
Anti-biotics limited
|
Formulation Development and Training
|
Guwahati
|
14. Karnataka
Anti-biotics and Pharmaceuticals Limited
|
Collaboration in the area of Biopharmaceuticals and
Natural Products for drug discovery.
|
Hajipur
|
15. Bengal
Chemicals and Fertilizers Limited Kolkata
|
Formulation Development and Training
|
Kolkata
|
16. Bengal
Chemicals and Fertilizers Limited Kolkata
|
Product Development and Training
|
Rae Bareli
|
17. Indian
Drugs & Pharmaceuticals Limited Rishikesh/Gurgaon
|
Formulation Development and Training
|
Post a Comment